FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079841006> ?p ?o ?g. }

• W2079841006 endingPage "1055" @default.
• W2079841006 startingPage "1054" @default.
• W2079841006 abstract "We read with interest the article by Sonneveld et al.,1 who reported an association between on-treatment hepatitis B surface antigen (HBsAg) levels and a sustained response to peginterferon alfa-2b in hepatitis B e antigen (HBeAg)–positive patients (n = 221). No HBsAg decline by week 12 of therapy was associated with a low chance of a sustained response (97% probability of nonresponse) and was proposed as an early stopping rule for peginterferon therapy. Because this rule needs to be validated in other studies, we investigated how the rule would have performed in HBeAg-positive patients treated with peginterferon alfa-2a during two independent, large-scale studies.2, 3 HBeAg-positive patients received peginterferon alfa-2a (180 μg/week) with or without lamivudine (100 mg/day) for 48 weeks as part of a phase 3 study2 (n = 542) or peginterferon alfa-2a (180 μg/week) for 48 weeks as part of the Nephrotic Syndrome Study Network (NEPTUNE) study (n = 136).3 Overall, the rates of HBeAg loss and hepatitis B virus (HBV) DNA levels < 10,000 copies/mL in the phase 3 and NEPTUNE peginterferon alfa-2a studies were similar (25% and 24%, respectively), and they were higher than those in Sonneveld et al.'s analysis (19%).1 In accordance with Sonneveld et al.'s data, the HBsAg decline was more pronounced in patients with a response 6 months post-treatment versus nonresponders. Patients with no HBsAg decline from the baseline to week 12 had 82% (80/97) and 71% (22/31) probabilities of nonresponse in the phase 3 and NEPTUNE studies, respectively; these were considerably lower than the probability of 97% in Sonneveld et al.'s study (Fig. 1). The probabilities of response in patients with no HBsAg decline were 18% (17/97) and 29% (9/31), respectively. Applying the stopping rule would have resulted in premature treatment discontinuation in some patients (17 and 9, respectively) who would have responded. HBeAg seroconversion 6 months post-treatment, rather than HBeAg loss and HBV DNA levels <10,000 copies/mL, was the primary endpoint in the peginterferon alfa-2a studies. Using this more robust indicator of sustained immune control would have resulted in some patients in the phase 3 and NEPTUNE studies (30 and 12, respectively) discontinuing their treatment prematurely if the stopping rule had been applied. Flowcharts for any decline in HBsAg levels from the baseline to week 12 with respect to the sustained response post-treatment. Response is defined as HBeAg loss and HBV DNA levels < 10,000 copies/mL. An asterisk indicates patients with HBsAg values available for the baseline, for weeks 12, 24, and 48 of therapy, and for 6 months post-treatment. A dagger indicates patients with HBsAg values available for the baseline and for week 12 of therapy. Differences in the study populations could explain the varying response rates and the fact that the proposed stopping rule could not be validated by the peginterferon alfa-2a analyses. Sonneveld et al.'s analysis1 was a European study in which only 20% of the patients were Asian, whereas the populations of the phase 3 and NEPTUNE peginterferon alfa-2a studies were predominantly Asian (>80%). This influenced the genotype distribution; Sonneveld et al.'s study had a high proportion of genotype A or D patients, whereas the peginterferon alfa-2a studies included predominantly genotype B and C patients. In combination with the differences in the treatment regimens (peginterferon alfa-2a versus peginterferon alfa-2b and 48 weeks of therapy versus 52 weeks) and in the numbers of patients included in the analyses, this may account for the differences in the results. Monitoring HBsAg levels during peginterferon therapy provides a good indication of the treatment response and helps in identifying early success. However, it is clear that further analysis is required either to identify an early stopping rule for peginterferon therapy that is valid for all genotypes or to develop genotype-specific algorithms. Teerha Piratvisuth M.D.*, Patrick Marcellin M.D. , * NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand, Service d'Hépatologie, Centre de Recherche Biologique Bichat Beaujon (Unité 773), Hôpital Beaujon, University of Paris, Clichy, France." @default.
• W2079841006 created "2016-06-24" @default.
• W2079841006 creator A5013246678 @default.
• W2079841006 creator A5045166316 @default.
• W2079841006 date "2011-03-01" @default.
• W2079841006 modified "2023-10-02" @default.
• W2079841006 title "Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients" @default.
• W2079841006 cites W1812279404 @default.
• W2079841006 cites W1973280003 @default.
• W2079841006 cites W1974933323 @default.
• W2079841006 cites W1982584241 @default.
• W2079841006 cites W2008517556 @default.
• W2079841006 cites W2011780953 @default.
• W2079841006 cites W2033837061 @default.
• W2079841006 cites W2052873131 @default.
• W2079841006 cites W2058141655 @default.
• W2079841006 cites W2061365719 @default.
• W2079841006 cites W2071222332 @default.
• W2079841006 cites W2082922804 @default.
• W2079841006 cites W2089671344 @default.
• W2079841006 cites W2135325091 @default.
• W2079841006 cites W2170132072 @default.
• W2079841006 doi "https://doi.org/10.1002/hep.24136" @default.
• W2079841006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21374671" @default.
• W2079841006 hasPublicationYear "2011" @default.
• W2079841006 type Work @default.
• W2079841006 sameAs 2079841006 @default.
• W2079841006 citedByCount "32" @default.
• W2079841006 countsByYear W20798410062012 @default.
• W2079841006 countsByYear W20798410062013 @default.
• W2079841006 countsByYear W20798410062014 @default.
• W2079841006 countsByYear W20798410062015 @default.
• W2079841006 countsByYear W20798410062016 @default.
• W2079841006 countsByYear W20798410062017 @default.
• W2079841006 countsByYear W20798410062018 @default.
• W2079841006 countsByYear W20798410062019 @default.
• W2079841006 crossrefType "journal-article" @default.
• W2079841006 hasAuthorship W2079841006A5013246678 @default.
• W2079841006 hasAuthorship W2079841006A5045166316 @default.
• W2079841006 hasBestOaLocation W20798410061 @default.
• W2079841006 hasConcept C126322002 @default.
• W2079841006 hasConcept C203014093 @default.
• W2079841006 hasConcept C2522874641 @default.
• W2079841006 hasConcept C2775940106 @default.
• W2079841006 hasConcept C2776235749 @default.
• W2079841006 hasConcept C2777382497 @default.
• W2079841006 hasConcept C2777410769 @default.
• W2079841006 hasConcept C2777869810 @default.
• W2079841006 hasConcept C2780040827 @default.
• W2079841006 hasConcept C2780593183 @default.
• W2079841006 hasConcept C3020491458 @default.
• W2079841006 hasConcept C71924100 @default.
• W2079841006 hasConcept C90924648 @default.
• W2079841006 hasConceptScore W2079841006C126322002 @default.
• W2079841006 hasConceptScore W2079841006C203014093 @default.
• W2079841006 hasConceptScore W2079841006C2522874641 @default.
• W2079841006 hasConceptScore W2079841006C2775940106 @default.
• W2079841006 hasConceptScore W2079841006C2776235749 @default.
• W2079841006 hasConceptScore W2079841006C2777382497 @default.
• W2079841006 hasConceptScore W2079841006C2777410769 @default.
• W2079841006 hasConceptScore W2079841006C2777869810 @default.
• W2079841006 hasConceptScore W2079841006C2780040827 @default.
• W2079841006 hasConceptScore W2079841006C2780593183 @default.
• W2079841006 hasConceptScore W2079841006C3020491458 @default.
• W2079841006 hasConceptScore W2079841006C71924100 @default.
• W2079841006 hasConceptScore W2079841006C90924648 @default.
• W2079841006 hasIssue "3" @default.
• W2079841006 hasLocation W20798410061 @default.
• W2079841006 hasLocation W20798410062 @default.
• W2079841006 hasOpenAccess W2079841006 @default.
• W2079841006 hasPrimaryLocation W20798410061 @default.
• W2079841006 hasRelatedWork W1556816728 @default.
• W2079841006 hasRelatedWork W2010301081 @default.
• W2079841006 hasRelatedWork W2142153682 @default.
• W2079841006 hasRelatedWork W2164269826 @default.
• W2079841006 hasRelatedWork W2347701360 @default.
• W2079841006 hasRelatedWork W2377909279 @default.
• W2079841006 hasRelatedWork W2382375426 @default.
• W2079841006 hasRelatedWork W2771386081 @default.
• W2079841006 hasRelatedWork W2953442664 @default.
• W2079841006 hasRelatedWork W3031056812 @default.
• W2079841006 hasVolume "53" @default.
• W2079841006 isParatext "false" @default.
• W2079841006 isRetracted "false" @default.
• W2079841006 magId "2079841006" @default.
• W2079841006 workType "article" @default.